Literature DB >> 2670928

Comparison of the human immunodeficiency virus type 1 and 2 proteases by hybrid gene construction and trans-complementation.

S F Le Grice1, R Ette, J Mills, J Mous.   

Abstract

To determine the cleavage specificity of the proteases of the type 1 and 2 human immunodeficiency viruses (HIV-1, HIV-2), we interchanged this domain of the polymerase (pol) genes and analyzed the maturation programs of the chimeric polyproteins in an Escherichia coli expression system. In both cases, release of reverse transcriptase and integrase was observed, together with the respective 10-kDa protease form resulting from autocatalysis, although the maturation proceeded less efficiently compared to the homologous system. In further experiments, the ability of both HIV-1 and HIV-2 proteases to release in vivo gag p24 from an in-frame fusion of the full length gag and protease precursors was analyzed. In either case, p24 was released, albeit with greater efficiency in the heterologous gene construction. In vitro mixed lysate experiments with the HIV-1 gag precursor furthermore demonstrate that both enzymes respond to the aspartyl proteinase inhibitor pepstatin A. Taken together, these results illustrate that although different cleavage recognition sequences exist for HIV-1 and -2, they are amenable to the proteases of both viruses, but additionally that subtle differences in the mode of action of both enzymes are observable.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2670928

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Insertion of a peptide from MuLV RT into the connection subdomain of HIV-1 RT results in a functionally active chimeric enzyme in monomeric conformation.

Authors:  P K Pandey; N Kaushik; T T Talele; P N Yadav; V N Pandey
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

2.  Properties of avian retrovirus particles defective in viral protease.

Authors:  L Stewart; G Schatz; V M Vogt
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.

Authors:  D Serio; T A Rizvi; M Cartas; V S Kalyanaraman; I T Weber; H Koprowski; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

4.  Reverse transcriptase and protease activities of avian leukosis virus Gag-Pol fusion proteins expressed in insect cells.

Authors:  L Stewart; V M Vogt
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  trans-acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase.

Authors:  L Stewart; V M Vogt
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Reconstitution in vitro of RNase H activity by using purified N-terminal and C-terminal domains of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Z Hostomsky; Z Hostomska; G O Hudson; E W Moomaw; B R Nodes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

7.  Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants.

Authors:  C T Wang; E Barklis
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 and type 2 protease monomers are functionally interchangeable in the dimeric enzymes.

Authors:  C E Patterson; R Seetharam; C A Kettner; Y S Cheng
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase.

Authors:  S F Le Grice; T Naas; B Wohlgensinger; O Schatz
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  HIV-1 RT-associated ribonuclease H displays both endonuclease and 3'----5' exonuclease activity.

Authors:  O Schatz; J Mous; S F Le Grice
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.